Cataract Therapeutics - A Pipeline Analysis Report

Overview of the drug development pipeline for cataract therapeutics

It has been observed that the clouding of the eye’s natural lens, which lies behind iris and pupils as the major causes for cataract and is characterized by clouded, blurred, or dim vision. Cataract can start at any age, and sometimes, it may be present from birth. This condition begins when the protein in the eye forms clumps and prevents the lens from sending clear images to the retina. Companies are focusing on developing molecules with heat shock proteins, also known as alpha crystalline, which helps prevent misfolded proteins from aggregating in the lens of the eye. According to the Centers for Disease Control and Prevention (CDC), in 2017, people in the age group of above 40 years had a cataract in one or both eyes in the US. With the growing need for cataract therapeutics, monotherapy is the most efficient approach for the treatment of cataracts.

According to this pipeline analysis report, all of the drug molecules in the pipeline are being developed for the treatment of cataracts. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Pipeline analysis report on cataract therapeutics: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the cataract therapeutics. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Calpain Therapeutics
• Dompé farmaceutici
• EyeGate
• EyePoint Pharmaceuticals
• Genisphere

Therapeutic assessment of the drug development pipeline for cataract therapeutics by route of administration

• Ophthalmic
• Topical
• Unspecified

The ophthalmic route of administration (ROA) involves the application of the drug by in the form of a cream, an ointment, or a liquid drop while in the topical technique, the drug molecules are administered to body surfaces such as skin, mucous membranes, and eye.

Therapeutic assessment of the drug development pipeline for cataract therapeutics by therapy

• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for cataract therapeutics are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for cataract therapeutics?
• What are the companies that are currently involved in the development of drug molecules for cataract therapeutics?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.